GlassScriptPhysician profile
Katherine Scrivner
NPI 1972954741
$1,060.14
in general payments reported to CMS, 2019-2025
25 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.27 · 2020: $269 · 2021: $90.88 · 2022: $74.05 · 2023: $71.49 · 2024: $267 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $158.18 | 2019-2025 | Wegovy, Sogroya |
| Astrazeneca Pharmaceuticals LP | $106.67 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $85.38 | 2024-2025 | Skytrofa |
| Sanofi-Aventis U.S. LLC | $73.01 | 2019-2024 | |
| Lilly USA, LLC | $61.39 | 2020 | |
| Dexcom, INC. | $58.49 | 2020-2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $56.91 | 2020 | |
| Sanofi Pasteur INC. | $53.35 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $47.38 | 2024 | |
| Merck Sharp & Dohme LLC | $40.51 | 2020-2024 | Gardasil 9, Gardasil, Vaxelis |
| Collegium Pharmaceutical, INC. | $33.05 | 2025 | Jornay Pm |
| Alexion Pharmaceuticals, INC. | $29.56 | 2025 | Strensiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.02 | 2020 | |
| Beta Bionics, INC. | $24.16 | 2024 | Ilet Bionic Pancreas |
| Azurity Pharmaceuticals, INC. | $22.87 | 2024 | Triptodur |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amphastar Pharmaceuticals, INC. | $21.96 | 2024 | |
| Alk-Abello, INC | $21.85 | 2025 | Neffy |
| Tandem Diabetes Care, INC. | $20.78 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $19.02 | 2024 | Gvoke Hypopen |
| Corium, LLC | $18.18 | 2023 | Azstarys |
| Tris Pharma INC | $17.80 | 2023 | Dyanavel Xr |
| Noven Therapeutics, LLC | $16.64 | 2024 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $16.60 | 2020 | |
| Amgen INC. | $14.81 | 2019 | |
| Kaleo, INC. | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Scrivner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.